HC Wainwright Issues Positive Forecast for ASMB Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Assembly Biosciences in a research note issued on Monday, March 24th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will earn ($1.54) per share for the quarter, up from their prior forecast of ($1.95). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.05) EPS, FY2027 earnings at ($12.07) EPS and FY2028 earnings at ($12.32) EPS.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The business had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million.

ASMB has been the topic of several other reports. Guggenheim began coverage on Assembly Biosciences in a report on Tuesday. They issued a “buy” rating and a $31.00 target price on the stock. StockNews.com lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Monday.

Assembly Biosciences Stock Up 0.8 %

NASDAQ:ASMB opened at $10.90 on Wednesday. The firm has a market cap of $81.78 million, a PE ratio of -1.62 and a beta of 0.62. The company’s 50-day moving average price is $12.63 and its two-hundred day moving average price is $14.99. Assembly Biosciences has a 12 month low of $10.27 and a 12 month high of $19.93.

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Assembly Biosciences by 5,137.3% in the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 3,442 shares during the period. Palumbo Wealth Management LLC bought a new position in shares of Assembly Biosciences in the 4th quarter valued at about $180,000. Marshall Wace LLP grew its position in shares of Assembly Biosciences by 16.5% during the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 2,098 shares during the period. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares during the last quarter. Finally, Man Group plc bought a new stake in shares of Assembly Biosciences during the fourth quarter worth approximately $309,000. Institutional investors own 19.92% of the company’s stock.

Insiders Place Their Bets

In other news, Director Michael Houghton acquired 3,202 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were purchased at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.10% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.